Diagnostic efficacy of endobronchial ultrasound-guided transbronchoscopic lung biopsy for identifying tuberculous nodules.

Diagnostic efficacy of endobronchial ultrasound-guided transbronchoscopic lung biopsy for identifying tuberculous nodules.

Publication date: Aug 26, 2024

Microbiological diagnosis of pulmonary tuberculosis (PTB) is hampered by a low pathogen burden, low compliance and unreliable sputum sampling. Although endobronchial ultrasound-guided transbronchoscopic lung biopsy (EBUS-TBLB) has been found to be useful for the assessment of intrapulmonary nodules in adults, few data are available for the clinical diagnosis of pulmonary tuberculosis. Here, we evaluated EBUS-TBLB as a diagnostic procedure in adult patients with radiologically suspected intrapulmonary tuberculous nodules. This was a retrospective analysis of patients admitted with pulmonary nodules between January 2022 and January 2023 at Hangzhou Red Cross Hospital. All patients underwent EBUS-TBLB, and lung biopsy samples were obtained during hospitalization. All samples were tested for Mycobacterium tuberculosis using acid‒fast smears, Bactec MGIT 960, Xpert MTB/RIF, next-generation sequencing (NGS), and DNA (TB‒DNA) and RNA (TB‒RNA). The concordance between different diagnostic methods and clinical diagnosis was analysed via kappa concordance analysis. The diagnostic efficacy of different diagnostic methods for PTB was analysed via ROC curve. A total of 107 patients were included in this study. Among them, 86 patients were diagnosed by EBUS-TBLB, and the overall diagnostic rate was 80. 37%. In addition, 102 enrolled patients had benign lesions, and only 5 were diagnosed with lung tumours. Univariate analysis revealed that the diagnostic rate of EBUS-TBLB in pulmonary nodules was related to the location of the probe. The consistency analysis and ROC curve analysis revealed that NGS had the highest concordance with the clinical diagnosis results (agreement = 78. 50%, _705 = 0. 558) and had the highest diagnostic efficacy for PTB (AUC = 0. 778). In addition, Xpert MTB/RIF + NGS had the highest concordance with the clinical diagnosis results (agreement = 84. 11%, _705 = 0. 667) and had the highest efficacy in the diagnosis of PTB (AUC = 0. 826). EBUS-TBLB is a sensitive and safe method for the diagnosis of pathological pulmonary nodules. Xpert MTB/RIF combined with NGS had the highest diagnostic efficacy and can be used in the initial diagnosis of PTB.

Open Access PDF

Concepts Keywords
Acidfast Adult
Biopsy Aged
Hangzhou Bronchoscopy
Mycobacterium Diagnostic efficacy
Tuberculosis Female
Humans
Image-Guided Biopsy
Lung
Male
Middle Aged
Mycobacterium tuberculosis
Next-generation sequencing technology
Pulmonary tuberculosis
Retrospective Studies
Sensitivity and Specificity
Tuberculosis, Pulmonary
Xpert MTB/RIF

Semantics

Type Source Name
disease MESH pulmonary tuberculosis
drug DRUGBANK Saquinavir
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH infection
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH death
disease MESH clinical importance
drug DRUGBANK Gold
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Rifampicin
drug DRUGBANK Tretamine
drug DRUGBANK K201
drug DRUGBANK Oxygen
drug DRUGBANK Aspartame
drug DRUGBANK Lysozyme
drug DRUGBANK Methionine
drug DRUGBANK Flunarizine
drug DRUGBANK Water
drug DRUGBANK Bisoprolol
drug DRUGBANK Trestolone
drug DRUGBANK Ethanol
disease MESH hypertension
disease MESH hepatitis
disease MESH diabetes mellitus
disease MESH pneumonia
disease MESH pulmonary aspergillosis
disease MESH lung disease
drug DRUGBANK Esomeprazole
disease MESH missed diagnosis
disease MESH lymphadenopathies
drug DRUGBANK Methyprylon
disease MESH complications
disease MESH aneurysms
drug DRUGBANK Medical air
drug DRUGBANK Ademetionine
drug DRUGBANK Bedaquiline
disease MESH Pathogenesis
disease MESH lung cancer
disease MESH idiopathic pulmonary fibrosis
disease MESH solitary pulmonary nodules
disease MESH sarcoidosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *